Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: Results in 36 patients

Gold, Jay E.; Ross, Susan D.; Krellenstein, Daniel J.; LaRosa, Felicia; Malamud, S.; Osband, Michael E.

doi:10.1016/0959-8049(94)00523-8

Cited by 14 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Study on CMV-specific T cells showed that the percentage of CMV tetramer + T cells did not significantly change from the beginning to the end of the culture, suggesting that CMV tetramer + T cells expanded with similar efficiency with the total CD8 T cells [27]. Thus, tumor-specific components of CIK cells might be responsible for the clinical benefit observed in some cancer patients [51]. …”

Section: Improving Cik Therapy For Epithelial Cancermentioning

confidence: 99%

Cytokine-induced killer cells promote antitumor immunity

Jiang

2013

J Transl Med

127

View full text Add to dashboard Cite

The number of immune cells, especially dendritic cells and cytotoxic tumor infiltrating lymphocytes (TIL), particularly Th1 cells, CD8 T cells, and NK cells is associated with increased survival of cancer patients. Such antitumor cellular immune responses can be greatly enhanced by adoptive transfer of activated type 1 lymphocytes. Recently, adoptive cell therapy based on infusion of ex vivo expanded TILs has achieved substantial clinical success. Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8 T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities against tumor cells. Preclinical studies of CIK cells in murine tumor models demonstrate significant antitumor effects against a number of hematopoietic and solid tumors. Clinical studies have confirmed benefit and safety of CIK cell-based therapy for patients with comparable malignancies. Enhancing the potency and specificity of CIK therapy via immunological and genetic engineering approaches and identifying robust biomarkers of response will significantly improve this therapy.

show abstract

Section: Improving Cik Therapy For Epithelial Cancermentioning

confidence: 99%

Cytokine-induced killer cells promote antitumor immunity

Jiang

2013

J Transl Med

127

View full text Add to dashboard Cite

show abstract

“…6,8,9 An early report in patients with metastatic melanoma were also encouraging with an objective response rate of greater than 20% reported. 10 A small multicenter randomized trial of ALT 1 cimetidine versus cimetidine alone in 90 patients with metastatic renal cell carcinoma, resulted in reports of a 21% objective response rate in the ALT arm compared to 5% in the cimetidine-alone arm, and a statistically significant survival advantage. 6 Survival was best in the subset of patients whose autologous lymphocytes secreted IL-1 at a concentration of more than 500 pg/mL.…”

Section: Adoptive Cellular Therapy Involves the Administration Of Celmentioning

confidence: 98%

Treatment of Human Solid Malignancies with Autologous Activated Lymphocytes and Cimetidine: A Phase II Trial of the Cancer Biotherapy Research Group

Dillman

Soori

DePriest

et al. 2003

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Gold [13] administered ALT to 36 patients with metastatic melanoma and amongst 33 evaluable patients there were four complete responses, four PRs and six patients with stable disease. Prolonged survival compared with historical controls was claimed for responding patients.…”

Section: Peripheral Blood Memory T-cellsmentioning

confidence: 99%

Current status of adoptive immunotherapy of malignancies

Morse

Clay

Lyerly

2002

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Adoptive immunotherapy involves the transfer of immune effectors with antitumour activity into the tumour bearing host. Early approaches such as lymphokine activator killer (LAK) cells and tumour infiltrating lymphocytes (TILs) have yielded occasional clinical responses. More recently, attempts to stimulate and/or select antigen-specific T-cells in vitro have demonstrated that tumour-specific adoptive immunotherapy is possible. These approaches require complicated and time consuming in vitro stimulation procedures. Therefore, genetic modification of bulk T-cell populations is an attempt to create a large population of T-cells with a single specificity. In addition to work being done to develop the most potent effector, other studies are working on improving T-cell trafficking to tumours and interfering with the tumour-induced immunosuppression that can impair in vivo T-cell activity.

show abstract

Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: Results in 36 patients

Cited by 14 publications

References 47 publications

Cytokine-induced killer cells promote antitumor immunity

Cytokine-induced killer cells promote antitumor immunity

Treatment of Human Solid Malignancies with Autologous Activated Lymphocytes and Cimetidine: A Phase II Trial of the Cancer Biotherapy Research Group

Current status of adoptive immunotherapy of malignancies

Contact Info

Product

Resources

About